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Background: Bone-targeted agents are widely used for the treatment of osteoporosis, the prevention of
cancer-therapy induced bone loss, and for reducing the risk of skeletal related events in patients with
metastatic disease. Despite widespread use, relatively little is known about the in vivo effect of these
agents on bone homeostasis, bone quality, and bone architecture in humans. Traditionally bone quality
has been assessed using a transiliac bone biopsy with a 7 mm ‘‘Bordier’’ core needle. We examined the
possibility of using a 2 mm ‘‘Jamshidi’’ core needle as a more practical and less invasive method to
assess bone turnover and potentially other tumor effects.
Methods: A pilot study on the feasibility of assessing bone quality and microarchitecture and tumor
invasion using a 2 mm bone marrow trephine was conducted. Patients underwent a posterior trans-iliac
trephine biopsy and bone marrow aspirate. Samples were analyzed for bone microarchitecture, bone
density, and histomorphometry. The study plan was to accrue three patients with advanced breast cancer
to assess the feasibility of the study before enrolling more patients.
Results: The procedure was well tolerated. The sample quality was excellent to analyze bone trabecular
microarchitecture using both microCT and histomorphometry. Intense osteoclastic activity was observed
in a patient with extensive tumor burden in bone despite intravenous bisphosphonate therapy.
Discussion: Given the success of this study for assessing bone microarchitecture, bone density, and
histomorphometry assessment using a 2 mm needle the study will be expanded beyond these initial three
patients for longitudinal assessment of bone-targeted therapy.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bone-targeted agents aimed at reducing osteoclastogenesis
including bisphosphonates and denosumab are widely used in
cancer patients. Their uses include; the treatment of osteoporosis,
prevention of cancer-therapy induced bone loss, reducing the risk
of skeletal related events, reducing pain, and improving quality of
life in patients with metastatic disease [1]. In cancer patients
these agents are administered systemically at high and frequent,
often monthly, doses and for extended periods of time relative to
their use in the treatment of osteoporosis. Despite this there is a. This is an open access article un
, The Ottawa Hospital Cancer
l.: þ1 613 737 7700x70170;
s).paucity of data about the in vivo effect of these agents on bone
homeostasis, bone quality, and microarchitecture in humans. This
topic has gained increasing attention recently with the awareness
of long term toxicities of bisphosphonates such as osteonecrosis
of the jaw (ONJ) and atypical fractures.[2,3].
Traditionally bone strength has been viewed as an integration
of bone quantity and bone quality [4]. Clinically, bone strength
and susceptibility to fracture is based on bone mineral density
(BMD) as reﬂected through dual energy X-ray absortiometry
(DEXA) scans [5]. This, however, has only modest sensitivity/
speciﬁcity [5,6], and only a small proportion of fracture risk
reduction is actually explained by bone density increases [7,8].
Clinical and laboratory evidence suggest mechanical properties,
in addition to BMD, play an important role in bone strength [9–11].
However, assessing bone quality requires invasive testing, tradi-
tionally with a 7–8 mm ‘‘Bordier’’ trephine of transiliac bone [12].der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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table and painful for the patient. Second, it is difﬁcult technically in
achieving an adequate sample in cancer patients on bone-targeted
agents as anecdotally the procedure is more challenging than in
patients with osteoporosis [13]. Previous data from cadavers has
demonstrated that the 2 mm trephine provides comparable results
to a 7 mm trephine [14]. A review of the literature revealed no
studies comparing the two trephine sizes in living cancer patients.
Given the widespread use of outpatient posterior iliac crest
bone marrow biopsies in hematology and oncology using a 2 mm
Jamshidi needle, we wanted to see if this would allow a more
practical, technically easier sampling amenable to routine screen-
ing of bone status in cancer patients.2. Methods
2.1. Subjects and design
This study was a pilot feasibility study performed in three
patients prior to starting a larger prospective, single-arm, non-
interventional feasibility study using a 2 mm trephine to assess
bone quality in breast cancer patients. Patients were required to
have: advanced breast cancer, with or without bone metastases
with or without bisphosphonate treatment, and an ECOG r2. All
patients enrolled underwent a bone mineral density assessment
using DEXA. The study was approved by the research ethics
committee at the Ottawa Hospital Cancer Centre, and all patients
provided written informed consent.
2.2. Bone specimen collection
Trans-iliac crest bone biopsy specimens were obtained from
the posterior iliac crest using a Jamshidi bone biopsy trephine
(diameter 2 mm) (Cardinal Health, Dublin, Ohio, United States of
America) (see Appendix 1). The samples underwent histomorpho-
metric analysis, microarchitectural analysis, and routine patholo-
gic assessment.
2.3. Histological and histomorphometrical analysis of bone
Hematoxyline and Eosin (HE), von Kossa and van Gieson
(VKVG), and tartrate-resistant acid phosphatase (TRAP) staining
of plastic sections of posterior iliac bone samples from three
patients were performed on plastic sections. As described else-
where, for plastic sectioning, bone samples ﬁxed in 4% PFA/PBS
were embedded in methyl methacrylate, and sectioned (7-mm
thickness), and von Kossa and van Gieson staining was applied
[15]. Unmineralized bone sections were analyzed using Osteo-
measure software (Osteometrics, Inc.). Images were taken at room
temperature using a light microscope (DM200; Leica) with a
20 (numerical aperture of 0.40) or 40 (numerical aperture ofTable 1
Demographic data of study patients.
Patient 1
Age 64
Menopause status Postmenopausal
BMI (kg/m2) 34.0
Smoking history None
BMD (t-score) 1.9 [L1–L2]
Breast cancer Metastatic to soft tissues
Current therapy Aromatase inhibitor
Bisphosphonate use and duration Nil
BMI¼body mass index, BMD¼ bone mineral density and L¼ lumbar spine (i.e. L1¼ﬁr0.65) objective. All histological images were captured using a
camera (DP72; Olympus), acquired with a DP2-BSW software
(XV3.0; Olympus), and processed using Photoshop (Adobe).
2.4. Three dimensional micro-computed tomography (3D microCT)
of bone samples
The core biopsy samples were scanned wet in 70% ethanol by
micro-CT at 40X magniﬁcation with a SkyScan 1072 (Skyscan,
Aartselaar, Belgium) and analyzed with a bone analysis software
(ver2.2f, Aartselaar, Belgium). Trabecular bone structure was
measured. Parameters were acquired with a rotation of 0.91
between each picture and the x-ray source set at 100 kV and
98 mA. The segmentation of the image was made by a global
threshold and a voxel size of 21.9021.9021.90 mm3; the same
threshold setting was used for all the samples. Architectural
measurements were made as previously described [16,17].
2.5. Bone mineral density measurements by DEXA
Core biopsies were subjected to bone mineral density (BMD)
analysis using a PIXIMUS bone densitometer (PIXIMUS TM, GE
medical systems, Schenectady, NY, USA). A quality control phan-
tom was used to calibrate the densitometer prior to each experi-
ment. All patients also underwent DEXA scanning.
2.6. Statistical analysis
The primary endpoint of this pilot study was to assess the
feasibility of obtaining sufﬁcient tissue using bone marrow aspirates
and trephine biopsy for histomorphometry. The secondary endpoint
was comparison between current bone mineral density and patho-
logical analysis of bone marrow trephine biopsy looking at histo-
morphometry, and micro-architecture analysis. Given this was a
pilot study simple descriptive statistics were used.3. Results
Between January and July 2011 three patients consented and
underwent outpatient biopsies. Patient number one and number
two received two biopsies from separate areas of the posterior
iliac crest. Patient three received a single biopsy. The demo-
graphic characteristics of each patient can be found in Table 1.
Notably, all patients were post-menopausal, had metastatic dis-
ease, and two were on long-term bisphosphonate therapy.4. 3D microCT data
Bone volume (BV/TV) ranged from 10.8 to 13.5% consistent
with the published literature [18]. Trabecular thickness (Tb.Th),
trabecular separation (Tb.Sp), trabecular number (Tb.N) and bonePatient 2 Patient 3
56 59
Postmenopausal Postmenopausal
19.5 27.9
None None
1.3 [L1–L4] 2.2 [L1–L4]
Extensive bone metastases Limited bone metastases
Aromatase inhibitor Aromatase inhibitor
Yes (3 years) Yes (2 years)
st lumbar vertebrae).
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the range published in the literature in post-menopausal women
[18]. 3D microCT data are located in Table 2. The accompanying
ﬁgures for each biopsy are located in Fig. 1.4.1. Bone histomorphometry
Hematoxylin–Eosin (HE) stain of the hisotology sections shows
the presence of tumor (T) in sample of patient 1 and 2 (Fig. 2).
Samples from patient 1 and patient 2 shows the presence of
osteoid (O) by von Kossa and van Gieson (VKVG) stain. Among the
microscopic ﬁeld presented only sample from patient 2 shows the
presence of osteoclasts (C) as evident by tartrate-resistant acid
phosphatase (TRAP) staining (third panel). Osteoblasts wereTable 2
Microarchitectural parameters and measurement of cellular activities in the
poster iliac crest assessed by histomorphometry and 3D microCT.
Sample ID Patient1 Patient 2 Patient 3
BV/TV (%) 10.9 13.5 10.8
Tb. Th (mm) 0.14814 0.173 0.132
Tb. Sp (mm) 0.726 0.570 0.575
Tb.N (mm) 0.741 0.781 0.819
Ct. Wi (mm) N/A N/A N/A
BS/TV (1/mm) 2.707 3.049 2.98
BV/TV: bone volume.
Tb.Sp: trabecular separation.
Ct.Wi: cortical width.
N/A: non-applicable.
Tb.Th: trabecular thickness.
Tb.N: trabecular number.
BS/TV: bone surface per tissue area.
21
Fig. 1. MicroCT images, forstained with toludine blue. Osteoblast and osteoclast numbers
per tissue area and bone perimeter are displayed in Table 3.5. Discussion
Despite the widespread use of bone-targeted agents in breast
cancer patients, there is a relative paucity of data about the
in vivo effect of these agents on bone homeostasis, bone quality,
and microarchitecture in humans [1]. This is not withstanding
that we are using increasingly potent agents at higher doses and
increased frequencies, relative to their use in the treatment of
osteoporosis. This is important as long-term bisphosphonate use
confers prolonged suppression of bone remodeling sites which
can have deleterious clinical effects [3,19–22].
Newer methods for assessing bone quality are under investigation,
such as microindentation technique and high-resolution peripheral
quantitative CT [23–25], but are regarded as exploratory. High
resolution-peripheral quantitative CT appears to be better than DEXA
at predicting fracture risk, but has not yet reached widespread clinical
use [24–27]. Further, the use of biochemical turnover markers [8] are
primarily used for monitoring treatment efﬁcacy and compliance, and
do not directly assess bone quality. Bone histomorphometry remains
the gold standard in evaluating bone status prior to and following
therapeutic interventions. However, this invasive procedure is not
amenable to routine use. In cancer patients bone marrow biopsy is
frequently used for pathological assessment and we explored the
possibility to extend its use to bone histomorphometric parameters.
We therefore assessed the feasibility of using 2mm core biopsies to
obtain additional information on in vivo bone biology indices.
The current study demonstrates that using a 2 mm Jamshidi is
feasible, practical and yields a sample sufﬁcient to determine
trabecular microarchitecture and bone turnover indices by both3
patient #1, #2, and #3.
20µM
MB
OB
20µM
MB
OB
20µM
MB
OB
Patient 1
Patient 2
Patient 3
HE VKVG TRAP Toludine Blue
Fig. 2. Histological and histomorphometric analysis of bone. Hematoxyline and Eosin (HE), von Kossa and van Gieson (VKVG), and tartrate-resistant acid phosphatase (TRAP)
staining of plastic sections of bone samples from three patients. HE stain shows the presence of tumor (T) in patient #2. Patient #1 and #2 shows the presence of osteoid volume
(O) by VKVG stain (middle panel). No osteoclast is seen in the ﬁeld shown for sample of patient #1. BM: bone marrow and MB: mineralized bone. Among the microscopic ﬁeld
presented only sample from patient #2 show the presence of osteoclasts (C) by TRAP stain (right panel). Osteoblasts were stained with toludine blue.
Table 3
Osteoblast and osteoclast count data.
Patient N.Ob/T.Ar N.Ob/B.Pm N.Oc/T.Ar N.Oc/B.Pm
1 142.57 14.55 2.22 0.22
2 142.57 16.98 6.68 0.80
3 100.25 10.91 0 0
N.Ob/T.Ar: number of osteoblasts/ tissue area N.Ob/B.PM: number of osteoblasts/
bone perimeter Oc/T.Ar: number of osteoclasts/ tissue area and N.Oc/B.PM:
number of osteoclasts/bone perimeter in different patient bone sections.
M. Fralick et al. / Journal of Bone Oncology 1 (2012) 69–7372microCT and histomorphometry. The beneﬁt of this technique is
that it provides qualitative information on the in vivo effect of bone-
targeted agents on bone quality.This technique may also provide a
feasible means of assessing bone quality in cancer patients on
therapies known to affect bone quality (e.g., tamoxifen, aromatase
inhibitors). Previous studies have used BMD in this setting, but it has
its limitations and is not able to assess bone quality [28–30]. The
importance of assessing bone quality and balancing the potential
risks against the beneﬁts of bone toxic agents will be of paramount
importance if such agents (e.g., exemestane) are used for primary
prevention of breast cancer [23,31].
The ﬁndings of this prospective, pilot study are limited by the
small sample size, but recruitment is currently under way to expand
the study cohort. Another important limitation is that preclinical
models have demonstrated that the effect of bisphosphonates on
bone turnover is highly site speciﬁc [32]. The implications are that
data from a single biopsy site (i.e. iliac crest) may not be representa-
tive of global bone quality [32,33]. There were, however, several
ﬁndings that merit consideration. Patient #1 had metastatic cancer
to soft tissues but no bone metastasis and was treated with
aromatase inhibitors but not with bisphosphonates. Bone histomor-
phometry revealed active bone turnover as indicated in Table 3. In
contrast patient #3 who had limited bone metastatic disease was
treated with both aromatase inhibitors and bisphosphonates and had
evidence of bone suppression with no active osteoclast detected.
Patient #2 was of particular interest because of extensive bone
metastasis by skeletal survey and its conﬁrmation by the presence ofmetastatic tumor on histomorphometric sections (Fig. 2). Interest-
ingly this patient had very active osteoclastic activitiy as indicated in
Table 3 despite treatment with intravenous bisphosphonates for
three years suggesting that bisphosphonates were unable to com-
pletely suppress turnover when tumor burden is high. Given our
sample size, it is premature to generalize our ﬁndings but it provides
a rationale to extend our study with a larger sample size to assess the
reproducibility of our ﬁndings and whether or not a 2 mm core will
be able to replace the use of 7 mm core biopsies.6. Conclusion
The 2 mm Jamshidi is feasible, practical, and yields an ade-
quate sample to assess bone structure and quality using microCT
and histomorphometry in breast cancer patients. Additional
samples are required to assess reproducibility, effect of bispho-
sphonates on bone quality and novel information on bone/tumor
interaction. Further research is required to determine whether
this technique may be to longitudinally assess bone quality in
cancer patients on long-term bone-targeted therapies.Acknowledgments
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Foundation grant KG 100766(to RK).Appendix A. Transilliac crest bone marrow aspirate
and trephine biopsy
Transilliac crest bone marrow aspirate and trephine biopsy will
be performed as an outpatient procedure with proper anesthesia
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top leg ﬂexed and the lower leg straight, or alternatively in the
supine position. Palpate the iliac crest, and mark the preferred sampling site
with a pen. Aseptic technique is employed, including sterile gloves and gown.
 The site is prepared with an antiseptic (eg, povidone-iodine or
chlorhexidine gluconate), scrubbed, and draped, exposing only
the site to be sampled. The skin and the underlying tissue to the periosteum are
inﬁltrated with a local anesthetic (eg, approximately 10 mL of
1% Xylocaine). A 10 mL syringe with a 25-gauge needle is used
to inject an initial 0.5 mL directly under the skin, raising a
wheal. A 22-gauge needle is used to penetrate deeper into the
subcutaneous tissue and the underlying periosteum, an area
roughly 1 cm in diameter. A skin incision is made with a small surgical blade, through
which the bone marrow aspiration needle, with a stylet locked
in place, is inserted. Once the needle contacts the bone, it is advanced by slowly
rotating clockwise and counterclockwise until the cortical
bone is penetrated and the marrow cavity is entered. Contact
with the marrow cavity is usually noted by a sudden reduction
in pressure. The depth of the penetration should not extend
beyond an initial 1 cm. Once within the marrow cavity, the stylet is removed. Using a
20 mL syringe, approximately 0.3 mL of bone marrow is
aspirated. The material collected for bone marrow slides is
not mixed with an anticoagulant, and it is processed immedi-
ately by a technologist.
Bone marrow biopsy: Patient preparation is to be followed in the manner previously
described for bone marrow aspiration. The needle, with stylet locked in place, is held with the palm
and index ﬁnger and repositioned so that a new insertion site
is created for biopsy sampling. Once the needle touches the
bone surface, the stylet is removed. Using ﬁrm pressure, slowly rotate the needle in an alternating
clockwise-counterclockwise motion, and advance it into the
bone marrow cavity to obtain an adequate bone marrow
specimen measuring approximately 1.6–3 cm in length. Rotate the needle along its axis to help loosen the sample, pull
back approximately 2–3 mm, and advance the needle again
slightly, at a different angle, to help secure the specimen. Following this procedure, slowly pull the needle out, while
rotating in an alternating clockwise and counterclockwise motion. Remove the specimen from the needle and introduce a probe
through the distal cutting end.
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